Libtayo has been approved for adults when curative surgery or radiation is not appropriate Libtayo has been approved for adults when curative surgery or radiation is not appropriate The Nationail ...

The plan of treatment for a 69-year-old patient with poorly differentiated, infiltrative, cutaneous squamous cell carcinoma was the topic of discussion among Dan Paul Zandberg, MD, and other ...

Regeneron has fleshed out additional positive data for blockbuster immunotherapy Libtayo (cemiplimab) as an adjuvant therapy in high-risk cutaneous squamous cell carcinoma (CSCC), as rival PD-1 ...

Introduction: Cutaneous squamous cell carcinoma (cSCC) is a common form of skin cancer. Less accessibility to the cSCC cell lines has limited analyses of this disease. Thus, we here aimed to establish ...

New authorisation marks major milestone in earlier treatment of skin cancer The European Commission has approved Libtayo (cemiplimab) as the first and only immunotherapy for adult patients with ...

Increased odds of positive margins were associated with tumors from the head and neck (OR 2.78), excision in a primary care facility (OR 2.20), and increased tumor thickness (OR 1.56). Increased odds ...

Final thoughts on unmet needs in the management of BCC and CSCC and how to approach future treatment of these diseases. Transcript Omid Hamid, MD: While we have made huge inroads into the therapy for ...

Editors from AJMC® spoke with Martin Dietrich, MD, PhD, a medical oncologist at Cancer Care Centers of Brevard in Rockledge, Florida, and assistant professor of internal medicine at the University of ...